Molecular Partners presented updated data on the Phase 1/2a trial of MP0533 at the ASH Annual Meeting. The trial showed clinical benefit and acceptable safety profiles across 9 dosing regimens, with accelerated step-up dosing leading to increased exposure. Six of eight responders had low bone marrow blast counts at baseline, indicating potential benefits for patients with AML. Results support further investigation in this patient population. The trial has shown promising results, with densified dosing regimens being well-tolerated and leading to improved serum exposure, offering potential in both relapsed/refractory and front-line AML settings. Further exploration of MP0533’s potential is warranted.

Read more at GlobeNewswire: Molecular Partners Presents Updated Data from Ongoing Phase